Replies to post #113 on Nkarta Inc (NKTX)

[NY1972]

Cancer is adapting. Why bother expressing ligands if the NK cells are not working anyway.

NKG2D surface down-modulation in freshly isolated NK cells from MDS patients may be a clinically useful “biomarker” of suppressed NK function.

[NY1972]

It will be interesting to see how this DT HER2 x NKG2D x CD16A engager works since it won't be impacted by the # of ligands on cancer cells.